PUBBLICAZIONI 2016
Cattaneo C., Zappasodi P., Mancini V., Annaloro C., Pavesi F., Skert C., Ferrario A., Todisco E., Saccà V., Verga L., Passi A., Da Vià M., Ferrari S., Mometto G., Petullà M., Nosari A., Rossi G.
Emerging resistant bacteria strains in bloodstream infections of acute leukaemia patients: results of a prospective study by the Rete Ematologica Lombarda (Rel).
ANN HEMATOL 2016; 95(12): 1955-1963.
________________________________________
Ronchetti D., Manzoni M., Todoerti K., Neri A., Agnelli L.
In Silico Characterization of miRNA and Long Non-Coding RNA Interplay in Multiple Myeloma.
GENES-BASEL 2016; 7(12): E107-.
________________________________________
Marchica V., Accardi F., Storti P., Mancini C., Martella E., Dalla Palma B., Bolzoni M., Todoerti K., Marcatti M., Schifano C., Bonomini S., Sammarelli G., Neri A., Ponzoni M., Aversa F., Giuliani N.
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?
INT J HEMATOL 2016; Epub ahead of print(): -.
________________________________________
Gentile M., Shanafelt T.D., Rossi D. , Laurenti L., Mauro F.R., Molica M., Cutrona G., Uccello G., Campanelli M., Vigna E., Tripepi G., Chaffee K.G., Parikh S.A., Bossio S., Recchia A.G., Innocenti I., Pasquale R., Neri A., Ferrarini M., Gaidano G., Foà R., Morabito F.
Validation of the CLL-IPI and comparison with the MDACC prognostic index: analysis of 1364 newly diagnosed patients.
BLOOD 2016; Epub ahead of print(): -.
________________________________________
Molica M., Shanafelt T.D., Giannarelli D., Gentile M., Mirabelli R., Cutrona G., Levato L., Di Renzo N., Di Raimondo F., Musolino C., Angrilli F., Famà R., Recchia A.G., Chaffee K.G., Neri A., Kay N.E., Ferrarini M., Morabito F.
The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients.
AM J HEMATOL 2016; 91(11): 1090-1095.
________________________________________
Colombo M. , Galletti S., Bulfamante G., Falleni M., Tosi D., Todoerti K., Lazzari E., Crews L.A., Jamieson C.H., Ravaioli S., Baccianti F., Garavelli S., Platonova N., Neri A., Chiaramonte R.
Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche.
ONCOTARGET 2016; 7(35): 56013-56029.
________________________________________
Valdora F., Cutrona G., Matis S., Morabito F., Massucco C., Emionite L., Boccardo S., Basso L., Recchia A.G., Salvi S., Rosa F., Gentile M., Ravina M., Pace D., Castronovo A., Cilli M., Truini M., Calabrese M., Neri A., Neumaier C.E., Fais F., Baio G., Ferrarini M.
A non-invasive approach to monitor chronic lymphocytic leukemia engraftment in a xenograft mouse model using ultra-small superparamagnetic iron oxide-magnetic resonance imaging (USPIO-MRI).
CLIN IMMUNOL 2016; 175(): 52-60.
________________________________________
Nobili L., Lionetti M., Neri A.
Long non-coding RNAs in normal and malignant hematopoiesis.
ONCOTARGET 2016; 7(31): 50666-50681.
________________________________________
Amodio N., Stamato M.A., Gullà A.M., Morelli E., Romeo E., Raimondi L., Pitari M.R., Ferrandino I., Misso G., Caraglia M., Perrotta I., Neri A., Fulciniti M., Rolfo C., Anderson K.C., Munshi N.C., Tagliaferri P., Tassone P.
Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma.
MOL CANCER THER 2016; 15(6): 1364-1375.
________________________________________
Musto P., Simeon V., Todoerti K., Neri A.
Primary Plasma Cell Leukemia: Identity Card 2016.
CURR TREAT OPTION ON 2016; 17(4): 19-.
________________________________________
Ronchetti D., Agnelli L., Taiana E., Galletti S., Manzoni M., Todoerti K., Musto P., Strozzi F., Neri A.
Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma.
ONCOTARGET 2016; 7(12): 14814-14830.
________________________________________
Minna E., Romeo P., Dugo M., De Cecco L., Todoerti K., Pilotti S., Perrone F., Seregni E., Agnelli L., Neri A., Greco A., Borrello M.G.
miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.
ONCOTARGET 2016; 7(11): 12731-12741.
________________________________________
Fulciniti M., Amodio N., Bandi R.L., Cagnetta A., Samur M.K., Acharya C., Prabhala R., D’Aquila P., Bellizzi D., Passarino G., Adamia S., Neri A., Hunter Z., Treon S.P., Anderson K.C., Tassone P., Munshi N.C.
miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth.
BLOOD CANCER J 2016; 6(): e380-.
________________________________________
Platonova N., Manzo T., Mirandola L., Colombo M. , Calzavara E., Vigolo E., Cermisoni G.C., De Simone D., Garavelli S., Cecchinato V., Lazzari E., Neri A., Chiaramonte R.
PI3K/AKT signaling inhibits NOTCH1 lysosome-mediated degradation.
GENE CHROMOSOME CANC 2016; Epub ahead of print(): -.
________________________________________
Van Roosbroeck K., Fanini F., Setoyama T., Ivan C., Rodriguez-Aguayo C., Fuentes-Mattei E., Xiao L., Vannini I., Redis R., D’Abundo L., Zhang X., Nicoloso M.S., Rossi S., Gonzalez-Villasana V., Rupaimoole R., Ferracin M., Morabito F., Neri A., Ruvolo P., Ruvolo V.R., Pecot C.V., Amadori D., Aruzzo L., Calin S., Wang X., You M.J., Ferrajoli A., Orlowski R.Z., Plunkett W., Lichtenberg T., Davuluri R.V., Berindan-Neagoe I., Negrini M., Wistuba I.I., Hagop K., Sood A.K., Lopez-Berestein G., Keating M.J., Fabbri M., Calin G.A.
Combining anti-miR-155 with chemotherapy for the treatment of lung cancers.
CLIN CANCER RES 2016; Epub ahead of print(): -.
________________________________________
Storti P., Marchica V., Airoldi I., Donofrio G., Fiorini E., Ferri V., Guasco D., Todoerti K., Silbermann R., Anderson J., Zhao W., Agnelli L., Bolzoni M., Martella E., Mancini C., Campanini N., Noonan D.M., Petronini P.G., Neri A., Aversa F., Roodman G.D., Giuliani N.
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo.
LEUKEMIA 2016; 30(12): 2351-2363.
________________________________________
Molica S., Digiesi G., D’Arena G., Mirabelli R., Antenucci A., Conti L., Gentile M., Musto P., Neri A., Morabito F.
Serum levels of soluble calreticulin predict for time to first treatment in early chronic lymphocytic leukaemia.
BRIT J HAEMATOL 2016; 175(5): 983-985.
________________________________________
Zinzani P.L., Pellegrini C., Cerciello G., Monaco F., Volpetti S., Peli A., Angelucci E., Corradini P., Cox M.C., Guarini A., Musso M., Bresciani P., Amato G., Billio A., Caparrotti G., Figuera A., Nassi L., Gaudio F., Grossi A., Onida F., Merli M., Rigacci L., Argnani L.
Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program.
LEUK LYMPHOMA 2016; 57(10): 2370-2374.
________________________________________
Onida F.
GvHD prophylaxis in non-haploidentical allogeneic peripheral blood stem cell transplantation: beyond the standard to prevent relapse in patients with high-risk chronic lymphoproliferative diseases?
EUR J HAEMATOL 2016; 96(1): 7-8.
________________________________________
Saraceni F., Bruno B., Lemoli R.M., Meloni G., Arcese W., Falda M., Ciceri F., Alessandrino E.P., Specchia G., Scimè R., Raimondi R., Bacigalupo A., Bosi A., Onida F., Rambaldi A., Bonifazi F., Olivieri A.
Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission.
BONE MARROW TRANSPL 2016; Epub ahead of print(): -.
________________________________________
Balakrishnan K., Fu M., Onida F., Wierda W.G., Keating M.J., Gandhi V.
Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic.
ONCOTARGET 2016; 7(26): 39458-39472.
________________________________________
Lucioni M. , Berti E., Arcaini L., Croci G.A., Maffi A., Klersy C., Goteri G., Tomasini C., Quaglino P., Riboni R., Arra M., Dallera E., Grandi V., Alaibac M., Ramponi A., Rattotti S., Cabras M.G., Franceschetti S., Fraternali-Orcioni G., Zerbinati N., Onida F., Ascani S., Fierro M.T., Rupoli S., Gambacorta M., Zinzani P.L., Pimpinelli N., Santucci M., Paulli M.
Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers.
CANCER MED-US 2016; 5(10): 2740-2755.
________________________________________
Barcellini W., Fattizzo B., Zaninoni A., Valli V., Ferri V., Gianelli U., Cortelezzi A.
Clinical evolution of autoimmune cytopenias to idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and bone marrow failure syndromes.
AM J HEMATOL 2016; Epub ahead of print(): -.
________________________________________
Barcellini W.
The clinical dilemma and management of red cell autoantibodies.
EXPERT REV HEMATOL 2016; 9(4): 325-327.
________________________________________
Zaja F., Barcellini W., Cantoni S., Carpenedo M., Caparrotti G., Carrai V., Di Renzo N., Santoro C., Di Nicola M., Veneri D., Simonetti F., Liberati A.M., *Ferla V., Paoloni F., Crea E., Volpetti S., Tuniz E., Fanin R.
Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
AM J HEMATOL 2016; 91(5): e293-e295.
________________________________________
Carrabba M., Barcellini W., Fabio G.
Use of Thrombopoietin-Receptor Agonist in CVID-Associated Immune Thrombocytopenia.
J CLIN IMMUNOL 2016; 36(5): 434-436.
________________________________________
Bianchi P., Schwarz K., Hogel J., Fermo E., Vercellati C., Grosse R., Van Wijk R., Van Zwieten R., Barcellini W., Zanella A., Heimpel H.
Analysis of a cohort of 101 CDAII patients: description of 24 new molecular variants and genotype-phenotype correlations.
BRIT J HAEMATOL 2016; 175(4): 696-704.
________________________________________
Marangon M., Vianelli N., Palandri F. , Mazzucconi M.G., Santoro C., Barcellini W., Fattizzo B., Volpetti S., Lucchini E., Polverelli N., Carpenedo M., Isola M., Fanin R., Zaia F.
Rituximab in immune thrombocytopenia: gender, age and response as predictors of long-term response.
EUR J HAEMATOL 2016; Epub ahead of print(): Epub ahead of print-.
________________________________________
Del Gobbo A., Fiori S., Ercoli G., Di Bernardo A., Parafioriti A., Fabris S., Iurlo A., Neri A., Bosari S., Gianelli U.
Primary Soft Tissue Lymphomas: Description of Seven Cases and Review of the Literature.
PATHOL ONCOL RES 2016; Epub ahead of print(): -.
________________________________________
Gianelli U., Cattaneo D., Bossi A., Cortinovis I., Boiocchi L., Liu Y.C., Augello C., Bonometti A., Fiori S., Orofino N., Orazi A., Iurlo A.
The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations.
MODERN PATHOL 2016; Epub ahead of print(): -.
________________________________________
Augello C., Cattaneo D., bucelli C., Terrasi A., Fermo E., Martinelli I., Iurlo A., Gianelli U.
CD18 promoter methylation is associated with a higher risk of thrombotic complications in primary myelofibrosis.
ANN HEMATOL 2016; 95(12): 1965-1969.
________________________________________
De Stefano V., Vannucchi A.M., Ruggeri M., Cervantes F., Alvarez-Larrán A., Iurlo A., Randi M.L., Pieri L., Rossi E., Guglielmelli P., Betti S., Elli E., Finazzi M.C., Finazzi G., Zetterberg E., Vianelli N., Gaidano G., Nichele I., Cattaneo D., Palova M., Ellis M.H., Cacciola E., Tieghi A., Hernandez-Boluda J.C., Pungolino E., Specchia G., Rapezzi D., Forcina A., Musolino C., Carobbio A., Griesshammer M., Barbui T.
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients.
BLOOD CANCER J 2016; 6(11): e493-.
________________________________________
Breccia M., Graffigna G., Galimberti S., Iurlo A., Pungolino E., Pizzuti M., Maggi A., Falzetti F., Capalbo S.F., Intermesoli T., Maffei S., Elena C., Melosi A., Simonetti F., Capochiani E., Seta R.D., Pacilli M., Luppi M., Di Renzo N., Mastrullo L., Trabacchi E., Vallisa D., Rapezzi D., Orlandi E.M., Gambacorti-Passerini C., Efficace F., Alimena G.
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis.
SUPPORT CARE CANCER 2016; 24(11): 4487-4493.
________________________________________
De Stefano V., Ruggeri M., Cervantes F., Alvarez-Larrán A., Iurlo A., Randi M.L., Elli E., Finazzi M.C., Finazzi G., Zetterberg E., Vianelli N., Gaidano G., Rossi E., Betti S., Nichele I., Cattaneo D., Palova M., Ellis M.H., Cacciola R., Tieghi A., Hernandez-Boluda J.C., Pungolino E., Specchia G., Rapezzi D., Forcina A., Musolino C., Carobbio A., Griesshammer M., Sant’Antonio E., Vannucchi A.M., Barbui T.
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists.
LEUKEMIA 2016; 30(10): 2032-2038.
________________________________________
Latagliata R., Stagno F., Annunziata M., Abruzzese E., Iurlo A., Guarini A., Fava C., Gozzini A., Bonifacio M., Sorà F., Leonetti Crescenzi S., Bocchia M. , Crugnola M., Castagnetti F. , Capodanno I., Galimberti S., Feo C., Porrini R., Pregno P., Rizzo M. , Antolino A., Mauro E., Sgherza N., Luciano L., Tiribelli M. , Russo Rossi A., Trawinska M.M., Vigneri P., Breccia M., Rosti G., Alimena G.
Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia.
NEOPLASIA 2016; 18(9): 536-540.
________________________________________
Soverini S., De Benedittis C., Castagnetti F. , Gugliotta G., Mancini M., Bavaro L., Polakova K.M., Linhartova J., Iurlo A., Russo D., Pane F. , Saglio G., Rosti G., Cavo M., Baccarani M., Martinelli G.
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants
BMC CANCER 2016; 16(): 572-572.
________________________________________
Soverini S., De Benedittis C., Papayannidis C., Polakova K.M., Venturi C., Russo D., Bresciani P., Iurlo A., Mancini M., Vitale A., Chiaretti S., Foà R., Abruzzese E., Sorà F., Kohlmann A., Haferlach T., Baccarani M., Cavo M., Martinelli G.
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients.
LEUKEMIA 2016; 30(7): 1615-1619.
________________________________________
Campanelli R., Fois G., Catarsi P., Poletto V., Villani L., Erba B.G., Maddaluno L., Jemos B., Salmoiraghi S., Guglielmelli P., Abbonante V., Di Buduo C.A., Balduini A., Iurlo A., Barosi G., Rosti G., Massa M., AGIMM . I.
Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis.
PLOS ONE 2016; 11(6): e0156990-e0156990.
________________________________________
Soverini S., De Benedittis C., Polakova K.M., Linhartova J., Castagnetti F. , Gugliotta G., Papayannidis C., Mancini M., Klamova H., Salvucci M., Crugnola M., Iurlo A., Albano F., Russo D., Rosti G., Cavo M., Baccarani M., Martinelli G.
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
ONCOTARGET 2016; 7(16): 21982-21990.
________________________________________
Abbonante V., Di Buduo C.A., Gruppi C., Malara A., Gianelli U., Celesti G., Anselmo A., Laghi L., Vercellino M., Visai L., Iurlo A., Moratti R., Barosi G., Rosti G., Balduini A.
Thrombopoietin/TGF-ß1 Loop Regulates Megakaryocyte Extracellular Matrix Component Synthesis.
STEM CELLS 2016; 34(4): 1123-1133.
________________________________________
Breccia M., Stagno F., Luciano L., Abruzzese E., Annunziata M., D’adda M., Maggi A., Sgherza N., Russo Rossi A., Pregno P., Castagnetti F. , Iurlo A., Latagliata R., Cedrone M., Di Renzo N., Sorà F., Rege-Cambrin G., La Nasa G., Scortechini A.R., Greco G., Franceschini L., Sica S., Bocchia M. , Crugnola M., Orlandi E., Guarini A., Specchia G., Rosti G., Saglio G., Alimena G.
Dasatinib first-line: Multicentric Italian experience outside clinical trials.
LEUKEMIA RES 2016; 40(): 24-29.
________________________________________
Efficace F., Rosti G., Breccia M., Cottone F., Giesinger J.M., Stagno F., Iurlo A., Russo Rossi A., Luciano L., Martino B., Galimberti S., Turri D., Bergamaschi M. , Tiribelli M. , Fava C., Angelucci E., Mandelli F., Baccarani M.
The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia.
ANN HEMATOL 2016; 95(2): 211-219.
________________________________________
Arcaini L., Besson C., Frigeni M., Fontaine H., Goldaniga M., Casato M., Visentini M., Torres H.A., Loustaud-Ratti V., Peveling-Oberhag J., Fabris P., Rossotti R., Zaja F., Rigacci L., Rattotti S., Bruno R., Merli M., Dorival C., Alric L., Jaccard A., Pol S., Carrat F., Ferretti V.V., Visco C., Hermine O.
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.
BLOOD 2016; 128(21): 2527-2532.
________________________________________
Santi R.M., Ceccarelli M., Catania G., Monagheddu C., Evangelista A., Bernocco E., Monaco F., Federico M., Vitolo U., Cortelazzo S., Cabras M.G., Spina M., Baldini L., Boccomini C., Chiappella A., Bari A., Luminari S., Calabrese S., Levis A., Visco C., Contino L., Ciccone G., Ladetto M.
PO-03 – Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL).
THROMB RES 2016; 140(Suppl.1): s177-s177.
________________________________________
Bari A., Marcheselli L., Marcheselli R., Pozzi S., Cox M.C., Baldessari C., Ferri P., Gobbi P., Baldini L., Tadmor T., Musto P., Federico M., Sacchi S.
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients.
BRIT J HAEMATOL 2016; Epub ahead of print(): -.
________________________________________
Marcheselli R., Bari A., Tadmor T., Marcheselli L., Cox M.C., Pozzi S., Ferrari A., Baldini L., Gobbi P., Aviv A., Pugliese G., Federico M., Polliack A., Sacchi S.
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients.
HEMATOL ONCOL 2016; Epub ahead of print(): -.
________________________________________
Neri A., Todoerti K., Lionetti M., Simeon V., Barbieri M., Nozza F., Vona G., Pompa A., Baldini L., Musto P.
Primary plasma cell leukemia 2.0: advances in biology and clinical management.
EXPERT REV HEMATOL 2016; 9(77): 1063-1073.
________________________________________
Bari A., Marcheselli R., Marcheselli L., Alvares I., Pozzi S., Ferri P., Lazzaro A., Fragasso A., Neri S., Baldini L., Carella A.M., Angrilli F., Guariglia R., Buda G., Stelitano C., Sacchi S., Gruppo Italiano Studio Linfomi G.
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up
ACTA HAEMATOL-BASEL 2016; 137(1): 7-14.
________________________________________
Breccia M., Abruzzese E., Iurlo A., Gozzini A., Isidori A., Gangemi D., Pregno P., Alimena G.
Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase.
HAEMATOL-HEMATOL J 2016; 101(): e267-e268.
________________________________________
Sacchi S., Marcheselli R., Bari A., Buda G., Molinari A.L., Baldini L., Vallisa D., Cesaretti M., Musto P., Ronconi S. , Specchia G., Silvestris F., Guardigni L., Ferrari A., Chiappella A., Carella A.M., Santoro A., Di Raimondo F., Marcheselli L., Pozzi S.
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.
HAEMATOL-HEMATOL J 2016; 101(5): e196-e199.
________________________________________
Lionetti M., Barbieri M., Manzoni M., Fabris S., Bandini C., Todoerti K., Nozza F., Rossi D. , Musto P., Baldini L., Neri A.
Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.
ONCOTARGET 2016; 7(16): 21353-21361.
________________________________________
Bono P., Orlandi A., Zoccoli A., Salvatore A., Annaloro C., Tagliaferri E., Lunghi G.
Quantiferon CMV assay in allogenic stem cell transplant patients.
J CLIN VIROL 2016; 79(): 10-11.
________________________________________
Barbieri M., Manzoni M., Fabris S., Ciceri G., Todoerti K., Simeon V., Musto P., Cortelezzi A., Baldini L., Neri A., Lionetti M.
Compendium of FAM46C gene mutations in plasma cell dyscrasias.
BRIT J HAEMATOL 2016; 174(4): 642-645.
________________________________________
Florimonte L., Orunesu E., Castellani M. , Longari V., Cortelezzi A.
18F-Choline PET/CT-Positive Lytic Bone Lesions in Prostate Cancer and Accidental Myeloma Detection.
CLIN NUCL MED 2016; 41(5): 394-396.
________________________________________
Reda G., Orofino N., Cassin R., *Sciumè M., Fattizzo B., Cortelezzi A.
Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.
EXPERT OPIN DRUG SAF 2016; 15(6): 865-873.
________________________________________
Orofino N., *Guidotti F., Cattaneo D., *Sciumè M., Gianelli U., Cortelezzi A., Iurlo A.
Marked eosinophilia as initial presentation of breast implant-associated anaplastic large cell lymphoma.
LEUK LYMPHOMA 2016; 57(11): 2712-2715.
________________________________________
Fattizzo B., Zaninoni A., Giannotta J.A., *Binda F., Cortelezzi A., Barcellini W.
Reduced 25-OH vitamin D in patients with autoimmune cytopenias, clinical correlations and literature review.
AUTOIMMUN REV 2016; 15(7): 770-775.
________________________________________
Iurlo A., Cattaneo D., Orofino N., Bucelli C., Fabris S., Cortelezzi A.
Anagrelide and Mutational Status in Essential Thrombocythemia.
BIODRUGS 2016; 30(3): 219-223.
________________________________________
Pieri L., Bonadonna P., Elena C., Papayannidis C., Grifoni F., Rondoni M., Girlanda S., Mauro M., Magliacane D., Elli E.M., Iorno M.L., Almerigogna F., Scarfì F., Salerno R., Fanelli T., Gesullo F., Corbizi Fattori G., Bonifacio M., Perbellini O., Artuso A., Soverini S., De Benedittis C., Muratori S., Pravettoni V., Cova V., Cortellini G., Ciceri F., Cortelezzi A., Martinelli G., Triggiani M., Merante S., Vannucchi A.M., Zanotti R.
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients.
AM J HEMATOL 2016; 91(7): 692-699.
________________________________________
Gugliotta L., Iurlo A., Gugliotta G., Tieghi A., Specchia G., Gaidano G., Scalzulli P.R., Rumi E., Dragani A., Martinelli V., Santoro C., Randi M.L., Tagariello G., Candoni A., Cattaneo D., Ricco A., Palmieri R., Liberati A.M., Langella M., Rago A., Bergamaschi M. , Monari P., Miglio R., Santoro U., Cacciola R., Rupoli S., Mastrullo L., Musto P., Mazzucconi M.G., Vignetti M., Cortelezzi A., Vianelli N., Martino B., De Stefano V., Passamonti F., Vannucchi A.M., Registro Italiano Trombocitemie R.
Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms.
LEUKEMIA RES 2016; 46(): 18-25.
________________________________________
Canesi M., Giordano R., Lazzari L., Isalberti M., Isaias I.U., Benti R., Rampini P., Marotta G., Colombo A., Cereda E., Dipaola M., Montemurro T., Viganò M., Budelli S., Montelatici E., Lavazza C., Cortelezzi A., Pezzoni G.
Finding a new therapeutic approach for no-option Parkinsonisms: mesenchymal stromal cells for progressive supranuclear palsy.
J TRANSL MED 2016; 14(1): 127-127.
________________________________________
Iurlo A., Dagna L., Cattaneo D., Orofino N., Bianchi P., Cavalli G., Doglioni C., Gianelli U., Cortelezzi A.
Erdheim-Chester Disease With Multiorgan Involvement, Following Polycythemia Vera: A Case Report.
MEDICINE (BALTIMORE) 2016; 95(20): e3697-e3697.
________________________________________
Zaninoni A., Imperiali F., Cattaneo A., Soverini G., *Binda F., Porretti L., Cortelezzi A., Barcellini W.
Detection of erythroblast antibodies in mitogen-stimulated bone marrow cultures from patients with myelodysplastic syndromes.
TRANSFUSION 2016; 56(8): 2037-2041.
________________________________________
Fang J., Liu X., Bolanos L., Barker B., Rigolino C., Cortelezzi A., Oliva E.N., Cuzzola M., Grimes H.L., Fontanillo C., Komurov K., MacBeth K., Starczynowski D.T.
A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes.
NAT MED 2016; 22(7): 727-734.
________________________________________
Iurlo A., Cattaneo D., Giunta M., Gianelli U., Fraquelli M., Cortelezzi A.
Reply To: Assessment of Liver and Spleen Stiffness in Patients With Myelofibrosis Using FibroScan and Shear Wave Elastography.
ULTRASOUND Q 2016; 32(3): 317-.
________________________________________
Reda G., Cassin R., Fabris S., Ciceri G., Fattizzo B., *Sciumè M., Orofino N., Gianelli U., Neri A., Cortelezzi A.
Biological and molecular characterization of a rare case of cutaneous Richter syndrome.
HEMATOL ONCOL 2016; Epub ahead of print](): -.
________________________________________
Platzbecker U., Avvisati G., Cicconi L., Thiede C., Paoloni F., Vignetti M., Ferrara F., Divona M., Albano F., Efficace F., Fazi P., Sborgia M., Di Bona E., Breccia M., Borlenghi E., Cairoli R., Rambaldi A., Melillo L., La Nasa G., Fiedler W., Brossart P., Hertenstein B., Salih H.R., Wattad M., Lübbert M., Brandts C.H., Hänel M., Rolling C., Schmitz N., Link H., Frairia C., Pogliani EM., Fozza C., D’Arco A., Di Renzo N., Cortelezzi A., Fabbiano F., Dohner K., Ganser A., Dohner H., Amadori S., Mandelli F., Ehninger G., Schlenk R.F., Lo Coco F.
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
J CLIN ONCOL 2016; Epub ahead of print](): -.
________________________________________
Lussana F., Intermesoli T., Gianni F., Boschini C., Masciulli A., Spinelli O., Oldani E., Tosi M., Grassi A., Parolini M., Audisio E., Cattaneo C., Raimondi R., Angelucci E., Cavattoni I.M., Scattolin A.M., Cortelezzi A., Mannelli F. , Ciceri F., Mattei D., Borlenghi E., Terruzzi E., Romani C., Bassan R., Rambaldi A.
Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome.
BIOL BLOOD MARROW TR 2016; 22(11): 1983-1987.
________________________________________
Del Papa N., Onida F., Zaccara E., Saporiti G., Maglione W., Tagliaferri E., Andracco R., Vincenti D., Montemurro T., Mircoli L., Vitali C., Cortelezzi A.
Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis.
BONE MARROW TRANSPL 2016; Epub ahead of print](): -.
________________________________________
Iurlo A., Nobile A., Latagliata R., Bucelli C., Castagnetti F. , Breccia M., Abruzzese E., Cattaneo D., Fava C., Ferrero D., Gozzini A., Bonifacio M., Tiribelli M. , Pregno P., Stagno F., Vigneri P., Annunziata M., Cavazzini F., Binotto G., Mansueto G., Russo S., Falzetti F., Montefusco E., Gugliotta G., Storti S., D’Addosio A.M., Scaffidi L., Cortesi L., Cedrone M., Rossi A.R., Avanzini P., Mauro E., Spadea A., Celesti F., Giglio G., Isidori A., Crugnola M., Calistri E., Sorà F., Rege-Cambrin G., Sica S., Luciano L., Galimberti S., Orlandi E.M., Bocchia M. , Tettamanti M., Alimena G., Saglio G., Rosti G., Mannucci P.M., Cortelezzi A.
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.
ONCOTARGET 2016; 7(48): 80083-80090.
________________________________________
Ronchetti D., Manzoni M., Agnelli L., Vinci C., Fabris S., Cutrona G., Matis S., Colombo M., Galletti S., Taiana E., Recchia A.G., Bossio S., Gentile M., Musolino C., Di Raimondo F., Grilli A., Bicciato S., Cortelezzi A., Tassone P., Morabito F., Ferrarini M., Neri A.
lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome.
BLOOD CANCER J 2016; 6(): e468-e468.
________________________________________
Fracchiolla N., Annaloro C., Fattizzo B., Cortelezzi A.
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) role in hematopoiesis and in hematologic diseases: A critical review.
TOXICOLOGY 2016; 374(): 60-68.
________________________________________
Motta I., Filocamo M., Poggiali E., Stroppiano M., Dragani A., Consonni D., Barcellini W., Gaidano G., Facchini L., Specchia G., Cappellini M.D., Splenomegaly Gaucher Disease study group.
A multicentre observational study for early diagnosis of Gaucher disease in patients with Splenomegaly and/or Thrombocytopenia.
EUR J HAEMATOL 2016; 96(4): 352-359.
________________________________________
Merli F., Luminari S., Gobbi P.G., Cascavilla N., Mammi C., Ilariucci F., Stelitano C., Musso M., Baldini L., Galimberti S., Angrilli F., Polimeno G., Scalzulli P.R., Ferrari A., Marcheselli L., Federico M.
Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
J CLIN ONCOL 2016; 34(11): 1175-1181.
________________________________________
Luminari S., Goldaniga M., Cesaretti M., Orsucci L., Tucci A., Pulsoni A., Salvi F., Arcaini L., Carella A.M., Tedeschi A., Pinto A., Stelitano C., Baldini L.
A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular non-Hodgkin’s Lymphoma.
LEUK LYMPHOMA 2016; 57(4): 880-887.
________________________________________
Calura E., Bisognin A., Manzoni M., Todoerti K., Taiana E., Sales G., Morgan GJ., Tonon G., Amodio N., Tassone P., Neri A., Agnelli L., Romualdi C., Bortoluzzi S.
Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients.
ONCOTARGET 2016; 7(3): 2367-2378.
________________________________________
Scarfò I., Pellegrino E., Mereu E., Kwee I., Agnelli L., Bergaggio E., Garaffo G., Vitale N., Caputo M., Machiorlatti R., Circosta P., Abate F., Barreca A., Novero D., Mathew S., Rinaldi A., Tiacci E., Serra S., Deaglio S., Neri A., Falini B., Rabadan R., Bertoni F., Inghirami G., Piva R.
Identification of a new subclass of ALK negative ALCL expressing aberrant levels of ERBB4 transcripts.
BLOOD 2016; 127(2): 221-232.
________________________________________
Gentile M., Cutrona G., Molica S., Ilariucci F., Mauro F.R., Di Renzo N., Di Raimondo F., Vincelli I., Todoerti K., Matis S., Musolino C., Fabris S., Lionetti M., Levato L., Zupo S., Angrilli F., Consoli U., Festini G., Longo G., Cortelezzi A., Musto P., Federico M., Neri A., Ferrarini M., Morabito F.
Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study.
EUR J HAEMATOL 2016; 96(1): 36-45.
________________________________________
Gentile M., Shanafelt T.D., Cutrona G., Molica S., Tripepi G., Alvarez I., Mauro F.R., Di Renzo N., Di Raimondo F., Vincelli I., Todoerti K., Matis S., Musolino C., Fabris S., Vigna E., Levato L., Zupo S., Angrilli F., Consoli U., Festini G., Longo G., Cortelezzi A., Arcari A., Federico M., Mannina D., Recchia A.G., Neri A., Kay N.E., Ferracin M., Morabito F.
A progression-risk score to predict treatment free survival for early stage chronic lymphocytic leukemia patients.
LEUKEMIA 2016; 30(6): 1440-1443.
________________________________________
